Hanmi Pharmaceutical Releases Amozaltan XQ for Hypertension and Dyslipidemia Treatment


Hanmi Pharmaceutical announced on February 7 that it has launched Amozaltan XQ, a combination drug consisting of four active ingredients for treatment of hypertension and dyslipidemia. It is an ethical-the-counter (ETC) drug comprised of amlodipine and losartan, which are used to treat hypertension, and rosuvastatin and ezetimibe, which are used to treat dyslipidemia.

With the recent product release, the Amozaltan family now consists of four products, including Amozaltan, Amozaltan Plus, and Amozaltan Q, administered at eighteen different doses.

A representative of Hanmi Pharmaceutical said, “53.8% of hypertension patients also suffer from dyslipidemia and thus must endure the hassle of taking multiple medications. Medication compliance among elderly patients is particularly low, thus necessitating the development of a combination drug with multiple active ingredients. [...] With our product lineup consisting of two-ingredient, three-ingredient, and four-ingredient combination drugs administered at eighteen doses, we will be able to improve convenience for healthcare professionals and patients.”

A Phase 3 clinical trial with 145 Korean patients suffering from both hypertension and dyslipidemia has proven the safety and efficacy of the newly released drug. According to Hanmi Pharmaceutical, Amozaltan XQ resulted in approximately 15.8mmHg drop in systolic blood pressure in patients whose blood pressure could not be controlled with rosuvastatin alone, and it also led to a 59% decrease in LDL-C compared to the baseline. No Dr. Kim Hyo-soo, Professor of Cardiology at Seoul National University, who was the principal investigator in the Phase 3 clinical trial stated, “Amozaltan XQ is a medication made with four active ingredients that are most commonly administered in combination, and it has been released in varying doses, making it more convenient to prescribe the drug. Also, patients are able to obtain the dose they need with fewer tablets, so it is expected to become quite popular. [...] It will be cost-effective and boost medication compliance, so it is expected to greatly contribute to the treatment of patients with cardio- or cerebrovascular diseases and to the prevention of recurrences.”

Woo Jong-soo, CEO of Hanmi Pharmaceutical, explained that “Amozaltan XQ, the world’s first four-ingredient combination drug, is a meaningful product that has been developed by integrating the original pharmaceutical preparation technologies of Hanmi Pharmaceuticals” and promised to “continually develop competitive products to better assist healthcare professionals and patients and remain as a proud Korean pharmaceutical company.”

Source: cheongnyeon-uisa